Free Trial

Truist Financial's Rating of Larimar Therapeutics on 3/25/2026

On March 25, 2026, Truist Financial updated its outlook on Larimar Therapeutics (NASDAQ:LRMR) with the action "Upgrade", setting a "Strong-Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Truist Financial Corporation

DateCompanyAction
11/11/2026
CoreWeave Inc. stock logo
CRWV
CoreWeave
Lower Price Target
11/11/2026
American Public Education, Inc. stock logo
APEI
American Public Education
Lower Price Target
11/11/2026
Carlsmed, Inc. stock logo
CARL
Carlsmed
Boost Price Target
11/11/2026
Camping World stock logo
CWH
Camping World
Lower Price Target
11/11/2026
Winnebago Industries, Inc. stock logo
WGO
Winnebago Industries
Boost Price Target
11/11/2026
Block, Inc. stock logo
XYZ
Block
Boost Price Target
More Ratings From Truist Financial Corporation